Characterization of Antiviral Resistance Mutations Among the Eastern Indian Hepatitis B Virus Infected Population

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2013 Feb 16

PMID 23409946

Citations 7

Authors

Rajesh Panigrahi

Avik Biswas

Binay Krishna De

Sekhar Chakrabarti

Runu Chakravarty

Affiliations

Soon will be listed here.

Abstract

Background: Antiviral therapy using nucleos(t)ide analogues (NAs) is an effective control measure of chronic hepatitis B virus (HBV) infection; however they need long term treatment. Presence of drug-resistance mutations may get in the way of the efficacy of antiviral therapy. Our study was aimed at defining the prevalence of HBV drug-resistance in HBVrt region in a population of 147 HBsAg positive patients.

Findings: HBV/D has shown multiple types of HBVrt mutations both among treatment naïve (65.0%, 13 of 20 HBV/D) and treated patients (56.2%, 9 of 16 HBV/D). In additional, several mutations, with a suggested role in drug resistance, were detected among the treatment naïve as well as the treated patients. The mutations reported to be involved in reduction of drug effectiveness, was common among non-responders to therapy as well as among the naïve patients. Notably, classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C /G/I -rtM204V/I-rtN236T-rtM250V) were not detected.

Conclusion: The prevalence of putative NAr mutations among non responders to therapy suggests that they might have role in reduced efficacy of currently available antivirals and requires further investigations.

Citing Articles

Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana.

Anderson M, Mangogola T, Phinius B, Mpebe G, Aimakhu C, Choga W Microorganisms. 2024; 12(6).

PMID: 38930589 PMC: 11205512. DOI: 10.3390/microorganisms12061207.

Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana.

Anderson M, Choga W, Moyo S, Bell T, Mbangiwa T, Phinius B Genes (Basel). 2018; 9(9).

PMID: 30205537 PMC: 6162474. DOI: 10.3390/genes9090453.

Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.

Choi Y, Lee S, Kim B World J Gastroenterol. 2018; 24(16):1708-1724.

PMID: 29713126 PMC: 5922991. DOI: 10.3748/wjg.v24.i16.1708.

Current Scenario of Hepatitis B and Its Treatment in India.

Ray G J Clin Transl Hepatol. 2017; 5(3):277-296.

PMID: 28936409 PMC: 5606974. DOI: 10.14218/JCTH.2017.00024.

Genotyping and Mutation Pattern in the Overlapping MHR Region of HBV Isolates in Southern Khorasan, Eastern Iran.

Ziaee M, Javanmard D, Sharifzadeh G, Namaei M, Azarkar G Hepat Mon. 2016; 16(10):e37806.

PMID: 27882062 PMC: 5111392. DOI: 10.5812/hepatmon.37806.

References

Stuyver L, Locarnini S, Lok A, Richman D, Carman W, Dienstag J . Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001; 33(3):751-7. DOI: 10.1053/jhep.2001.22166. View

Locarnini S, Mason W . Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2005; 44(2):422-31. DOI: 10.1016/j.jhep.2005.11.036. View

Borroto-Esoda K, Miller M, Arterburn S . Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007; 47(4):492-8. DOI: 10.1016/j.jhep.2007.06.011. View

Datta S, Panigrahi R, Biswas A, Chandra P, Banerjee A, Mahapatra P . Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization of viral variants with the immune escape G145R mutation. J Virol. 2009; 83(19):9983-92. PMC: 2748009. DOI: 10.1128/JVI.01905-08. View

Solmone M, Vincenti D, Prosperi M, Bruselles A, Ippolito G, Capobianchi M . Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2008; 83(4):1718-26. PMC: 2643754. DOI: 10.1128/JVI.02011-08. View

Liu B, Li T, Xu J, Li X, Dong J, Yan P . Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res. 2009; 85(3):512-9. DOI: 10.1016/j.antiviral.2009.12.006. View

Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert T, Gut J . Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol. 2009; 15(6):753-5. PMC: 2653447. DOI: 10.3748/wjg.15.753. View

Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F . Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. Antiviral Res. 2011; 92(2):382-5. DOI: 10.1016/j.antiviral.2011.08.013. View

Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M . The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol. 2008; 50(3):461-70. DOI: 10.1016/j.jhep.2008.07.038. View

10.

Bartholomeusz A, Locarnini S . Hepatitis B virus mutations associated with antiviral therapy. J Med Virol. 2006; 78 Suppl 1:S52-5. DOI: 10.1002/jmv.20608. View

11.

Lok A, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky J . Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46(1):254-65. DOI: 10.1002/hep.21698. View

12.

Chandra P, Biswas A, Datta S, Banerjee A, Panigrahi R, Chakrabarti S . Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection. J Viral Hepat. 2009; 16(10):749-56. DOI: 10.1111/j.1365-2893.2009.01129.x. View

13.

Norder H, Courouce A, Coursaget P, Echevarria J, Lee S, Mushahwar I . Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004; 47(6):289-309. DOI: 10.1159/000080872. View

14.

Bartholomeusz A, Locarnini S . Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006; 26(2):162-70. DOI: 10.1055/s-2006-939758. View

15.

Ismail A, Samuel P, Eapen C, Kannangai R, Abraham P . Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology. 2011; 55(1):36-44. DOI: 10.1159/000323521. View

16.

Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L . The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother. 2007; 51(7):2285-92. PMC: 1913255. DOI: 10.1128/AAC.01499-06. View

17.

Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G . Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol. 2009; 47(8):2544-50. PMC: 2725693. DOI: 10.1128/JCM.00045-09. View

18.

Biswas A, Banerjee A, Chandra P, Datta S, Panigrahi R, Dutta D . Variations in the functional domain of basal core promoter of hepatitis B virus among Eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population. J Med Virol. 2010; 83(2):253-60. DOI: 10.1002/jmv.21979. View